The road to resistance: EGFR mutation and cetuximab

Nature Medicine

Volumn 18, Issue 2, 2012, Pages 199-200

  Bardelli, Alberto ^a   Jänne, Pasi A ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PROTEIN N RAS; RAS PROTEIN; UNCLASSIFIED DRUG;

CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; COLORECTAL CANCER; DRUG BINDING; DRUG EFFICACY; DRUG TARGETING; EXTRACELLULAR FLUID; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; PRIORITY JOURNAL; RELAPSE; SHORT SURVEY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84856721608     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2646     Document Type: Short Survey

References (14)

1. Montagut, C. et al. Nat. Med. 18, 221-223 (2012).
2. Jonker, D.J. et al. N. Engl. J. Med. 357, 2040-2048 (2007).
3. Vermorken, J.B. et al. N. Engl. J. Med. 359, 1116-1127 (2008).
4. Karapetis, C.S. et al. N. Engl. J. Med. 359, 1757-1765 (2008).
5. De Roock, W. et al. Lancet Oncol. 11, 753-762 (2010).
6. Amado, R.G. et al. J. Clin. Oncol. 26, 1626-1634 (2008).
7. Bardelli, A. & Siena, S. J. Clin. Oncol. 28, 1254-1261 (2010).
8. Wadlow, R.C. et al. Oncologist published online, doi: 10.1634/theoncologist.2011-0452 (30 December 2011).
9. Jänne, P.A., Gray, N. & Settleman, J. Nat. Rev. Drug Discov. 8, 709-723 (2009).
10. Yonesaka, K. et al. Sci. Transl. Med. 3, 99ra86 (2011).
11. Bertotti, A. et al. Cancer Discov. 1, 509-523 (2011).
12. Benavente, S. et al. Clin. Cancer Res. 15, 1585-1592 (2009).
13. Li, C., Iida, M., Dunn, E.F., Ghia, A.J. & Wheeler, D.L. Oncogene 28, 3801-3813 (2009).
14. Lu, Y. et al. Cancer Res. 67, 8240-8247 (2007).